

15 July 2026

## RESULTS OF EXTRAORDINARY GENERAL MEETING

PERTH, Australia and SAN FRANCISCO, California – 15 July 2026

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, PYC Therapeutics Limited (the 'Company') provides the following information in relation to the resolutions contained in the Notice of Meeting dated 12 June 2026 and considered at today's Extraordinary General Meeting of Shareholders.

All resolutions were carried following a poll conducted at the meeting. The proxies received in respect of each resolution and the results of the poll are set out in the attached results summary.

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.*

### About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development<sup>1</sup>.

For more information, visit [pyctx.com](https://pyctx.com), or follow us on [LinkedIn](#).

### CONTACT US

**Investor relations and media contact**  
[investor@pyctx.com](mailto:investor@pyctx.com)



<sup>1</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank  
<https://doi.org/10.1101/2020.11.02.2022232>

## Summary of Results

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

| Resolution                                                               | Decided by<br>Show of<br>Hands (S) or<br>Poll (P) | Total Number of<br>Proxy Votes<br>exercisable by<br>proxies validly<br>appointed | Proxy Votes           |                      |         |                       | Poll Results (if<br>applicable) |                      |         | Results |
|--------------------------------------------------------------------------|---------------------------------------------------|----------------------------------------------------------------------------------|-----------------------|----------------------|---------|-----------------------|---------------------------------|----------------------|---------|---------|
|                                                                          |                                                   |                                                                                  | FOR                   | AGAINST              | ABSTAIN | PROXY'S<br>DISCRETION | FOR                             | AGAINST              | ABSTAIN | OUTCOME |
| 1 Approval of the PYC Therapeutics Limited Rights Plan                   | P                                                 | 421,972,545                                                                      | 395,776,876<br>93.79% | 26,172,616<br>6.20%  | 8,776   | 23,053<br>0.01%       | 395,799,929<br>93.80%           | 26,172,616<br>6.20%  | 8,776   | Carried |
| 2 Increase the constitutional cap on Non-Executive Director remuneration | P                                                 | 421,626,786                                                                      | 398,309,640<br>94.47% | 23,303,047<br>5.53%  | 26,535  | 14,099<br>0.00%       | 398,323,739<br>94.47%           | 23,303,047<br>5.53%  | 26,535  | Carried |
| 3 Approval to issue options to Dr. Rohan Hockings                        | P                                                 | 421,543,059                                                                      | 366,541,132<br>86.95% | 54,978,128<br>13.04% | 438,262 | 23,799<br>0.01%       | 366,564,931<br>86.96%           | 54,978,128<br>13.04% | 438,262 | Carried |